Latest posts
-
AmpliTech Group’s Division, AGMDC (AmpliTech Group Microwave Design Center), Inks Distribution Deal with Component Distributors Inc (CDI), a Global Value-Added Distributor of Electronic Components
HAUPPAUGE, NY, November 1, 2023 – AmpliTech Group, Inc (Nasdaq: AMPG), a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks and a worldwide distributor of packages and lids for integrated circuit assembly, and designer of complete 5G/6G systems, is proud to announce it has entered an agreement with Component
-
PRISM MarketView Highlights Its Spooktacular Zombie Index For Halloween
[et_pb_section admin_label=”section”] [et_pb_row admin_label=”row”] [et_pb_column type=”4_4″][et_pb_text admin_label=”Text”] NEW YORK, NY, October 30, 2023 – Halloween is the time of year where everyone has the chance to wear a costume and enjoy some spooky activities to celebrate the season such as indulging in a pumpkin flavored treat or visiting a haunted house. If you are still
-
PRISM MediaWire – Weekly Press Resume – Oct. 23 to Oct. 27, 2023
New York, New York, October 27, 2023 PRISM MediaWire – Weekly Press Resume Oct. 23 to Oct. 27, 2023 Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference Metatron Partners with MML Marketing, Boasting a Proven Track Record of $19M in Sales Argentum 47, Inc. Moves into Online Cloud Business with New SaaS
-
10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis
NEW YORK, NY, October 24, 2023 – The biotech sector, known for its exponential growth potential, is currently facing highly challenging market conditions. Influences like rising inflation, geopolitical tensions, and looming economic recessions have led to a sharp decline in the sector. Consequently, many small and micro-cap biotech companies are trading at all-time lows, with
-
SELLAS Advances Blood Cancer Treatment with “Tremendous Therapeutic Promise”
October 11, 2023 SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has reported two significant milestones this week as it pursues development of its drug candidate, SLS009 for hematological malignancies. “SLS009 is a novel and highly selective CDK9 inhibitor which, to date, has shown tremendous therapeutic promise across multiple blood cancers.” Angelos Stergiou, MD, ScD h.c.,
-
PRISM MarketView Launches Mental Health Index on World Mental Health Day
Index Highlights Innovative Companies Addressing the Unseen Challenges of Mental Disorders New York City, October 11, 2023 – In honor of World Mental Health Day, which raises awareness of mental health issues on a global scale, PRISM MarketView has introduced the Prism Emerging Mental Health Index, a proprietary index focused on pioneering stocks offering innovative
-
AmpliTech CEO Fawad Maqbool to Deliver Fireside Chat at Maxim Group’s TMT Conference
Virtual Presentation on Wednesday, October 11th at 4:00 pm ET HAUPPAUGE, NY, October 9, 2023 – AmpliTech Group, Inc (Nasdaq: AMPG), a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks, as well as a worldwide distributor of packages and lids for integrated circuit assembly, today announced that Chief Executive
-
AmpliTech’s Satcom Systems Subdivision Receives Orders from Major Media Companies
Specialty Microwave Subdivision Achieves a Record $1mm Bookings for 2023 HAUPPAUGE, NY, October 4, 2023 – AmpliTech Group, Inc (Nasdaq: AMPG), a designer, developer, and manufacturer of state-of-the-art signal-processing components for satellite, 5G, and other communications networks, as well as a worldwide distributor of packages and lids for integrated circuit assembly, is thrilled to announce new
-
SKYX to Significantly Expand Market Penetration with QUOIZEL Collaboration
“In my 32 years in the lighting business. It is by far the most disruptive technology I have seen and will transform the lighting industry from the old existing hardwire installation method to a safe plug-and-play installation method.” Rick Seidman, Chief Executive Officer of QUOIZEL September 28, 2023 Disruptive platform technology company, SKYX (Nasdaq: SKYX) will
-
SELLAS SLS009 Phase 1 Clinical Study Successfully Achieves All Primary and Secondary Endpoints
September 22, 2023 Late-stage biopharmaceutical company, SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) has announced positive topline data for the patient group with relapsed/refractory (r/r) lymphomas from its Phase 1 dose-escalation trial of its CDK9 inhibitor, SLS009 (GFH009). We are excited to share strong topline data from the Phase 1 trial of SLS009 in lymphoma patients. The